1
Clinical Trials associated with IgA VENBETA6890Phase 1, Randomized, Placebo-Controlled, Blinded Study in Healthy Adults Challenged With Enterotoxigenic Escherichia Coli, of the Safety, Tolerability and Anti-Diarrheal Activity of VENBETA6890, an Orally Administered, Human Monoclonal IgA
This is a phase 1, randomized, placebo-controlled, blinded study in up to 36 healthy adults, aged 18-45 years, challenged with Enterotoxigenic Escherichia coli, evaluating the safety, tolerability and anti-diarrheal activity of VENBETA6890, an orally administered, human monoclonal IgA.
100 Clinical Results associated with IgA VENBETA6890
100 Translational Medicine associated with IgA VENBETA6890
100 Patents (Medical) associated with IgA VENBETA6890
100 Deals associated with IgA VENBETA6890